Medtronic (MDT)'s CEO "is One of the Finest People," Says Jim Cramer

We recently published 13 Stocks That Crossed Jim Cramer’s Radar. Medtronic plc (NYSE:MDT) is one of the stocks Jim Cramer discussed.

Medtronic plc (NYSE:MDT) is a medical technology company that makes and sells devices for cardiovascular, neuroscience, and surgical applications. Cramer has discussed the firm on a handful of occasions in 2025. One such discussion occurred in May, when the CNBC TV host called the stock “inconsistent” despite Medtronic plc (NYSE:MDT) delivering strong numbers. The firm’s latest earnings report came earlier this week and saw it increase its fiscal year 2026 revenue growth to 5.5% and its EPS guidance to $5.62 – $5.66 per share. Medtronic plc (NYSE:MDT)’s $9 billion in fiscal second-quarter revenue and $1.36 in earnings also beat analyst estimates as CEO Geoffrey Martha attributed the performance to the overall strength in medical procedures. Cramer discussed the firm’s CEO and its businesses:

“What does the market like? Well it likes Merck on the Winrevair trial. Obviously we know it likes Amgen, you’re a high. But it loves Medtronic. . .Geoffrey Martha is one of the finest people I’ve ever met and I’ve been waiting for the earnings explosion. Well we got it today, and I think that, believe it or not, even up here, it’s a buy. Because they’ve got a series of like, where they are with ablations. Where they are with diabetes, which are spinning off. Their cardiovascular really is second to none. I am finally so gratified about their neuroscience. Which I have worked with them to be able to say, look, guys you have to make breakthroughs, in the toughest area, neuroscience, and I told Geoff, personally, I said I need this. And he, committed, and he’s delivered. He’s quite a man. And this is good stuff.

“[Responding to David’s comment about share price movement] They have reverse head and shoulders I know you care. But I am so impressed, with what they’ve done. And I’ve got to tell you, they are, when they get the diabetes business separated, cause I don’t like the diabetes business, the stock is going to trade up even more.

“[After David asked if he believes the stock’s got more to go through after the separation] Oh, I do believe this is the breakout I’ve been waiting from Geoff, he delivered, and he’s a sensational guy who cares tremendously about patients [inaudible].”

The latest remarks represent Cramer’s continued optimism for Medtronic plc (NYSE:MDT) as he had commented in January:

“Medtronic is doing so many things, they’re going to have mid single digit growth, I really like them.”

While we acknowledge the potential of MDT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.